Page 373 - Williams Hematology ( PDFDrive )

348 Part V: Therapeutic Principles Chapter 22: Pharmacology and Toxicity of Antineoplastic Drugs 349

71. Estey EH, Kurzrock R, Kantarjian HM, et al: Treatment of hairy cell leukemia with 103. Gutierrez M, Chabner BA, Pearson D, et al: Role of a doxorubicin-containing regi-
2-chlorodeoxyadenosine (2-CdA). Blood 79:882–887, 1992. men in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH. J Clin
72. Albertoni M, Daub DM, Arden KC, et al: Genetic instability leads to loss of both p53 Oncol 18:3633–3642, 2000.
alleles in a human glioblastoma. Oncogene 16:321–326, 1998. 104. Kane RC, McGuinn WD, Dagher R, et al: Dexrazoxane (Totect): FDA review and
73. Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 340:952–956, 1992. approval for the treatment of accidental extravasation following intravenous anthracy-
74. Crews KR, Wimmer PS, Hudson JQ, et al: Pharmacokinetics of 2-chlorodeoxyade- cline chemotherapy. Oncologist 13:445–450, 2008.
nosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J 105. Moreb JS, Oblon DJ: Outcome of clinical congestive heart failure induced by anthracy-
Pediatr Hematol Oncol 24:677–680, 2002. cline chemotherapy. Cancer 70:2637–2641, 1992.
75. de Wolf C, Jansen R, Yamaguchi H, et al: Contribution of the drug transporter ABCG2 106. Ichikawa Y, Ghanefar M, Bayeva M, et al: Cardiotoxicity of doxorubicin is mediated
(breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Can- through mitochondrial iron accumulation. J Clin Invest 124:617–630, 2014.
cer Ther 7:3092–3102, 2008. 107. Aryal B, Jeong J, Rao VA: Doxorubicin-induced carbonylation and degradation of
76. Bonate PL, Arthaud L, Cantrell WR Jr, et al: Discovery and development of clofarabine: cardiac myosin binding protein C promote cardiotoxicity. Proc Natl Acad Sci U S A
A nucleoside analogue for treating cancer. Nat Rev Drug Discov 5:855–863, 2006. 111:2011–2016, 2014.
77. Sanford M, Lyseng-Williamson KA: Nelarabine. Drugs 68:439–447, 2008. 108. Burstein HJ, Winer EP: Primary care for survivors of breast cancer. N Engl J Med
78. Steis RG, Urba WJ, Kopp WC, et al: Kinetics of recovery of CD4+ T cells in peripheral 343:1086–1094, 2000.
blood of deoxycoformycin-treated patients. J Natl Cancer Inst 83:1678–1679, 1991. 109. Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med-
79. Halsey C, Roberts IA: The role of hydroxyurea in sickle cell disease. Br J Haematol Intern Med 125:47–58, 1996.
120:177–186, 2003. 110. Lipshultz SE, Alvarez JA, Scully RE: Anthracycline associated cardiotoxicity in survi-
80. Platt OS: Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358: vors of childhood cancer. Heart 94:525–533, 2008.
1362–1369, 2008. 111. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute mye-
81. Sterkers Y, Preudhomme C, Laï JL, et al: Acute myeloid leukemia and myelodysplastic loid leukemia/myelodysplastic syndrome and other secondary malignancies in pediat-
syndromes following essential thrombocythemia treated with hydroxyurea: High pro- ric Hodgkin’s disease. J Clin Oncol 25:493–500, 2007.
portion of cases with 17p deletion. Blood 91:616–622, 1998. 112. Salzer WL, Devidas M, Carroll WL, et al: Long-term results of the pediatric oncology
82. Madoc-Jones H, Mauro F: Interphase action of vinblastine and vincristine: Differences group studies for childhood acute lymphoblastic leukemia 1984–2001: A report from
in their lethal action through the mitotic cycle of cultured mammalian cells. J Cell Phys- the children’s oncology group. Leukemia 24:355–370, 2010.
iol 72:185–196, 1968. 113. Mistry AR, Felix CA, Whitmarsh RJ, et al: DNA topoisomerase II in therapy-related
83. Cabral FR, Brady RC, Schibler MJ: A mechanism of cellular resistance to drugs that acute promyelocytic leukemia. N Engl J Med 352:1529–1538, 2005.
interfere with microtubule assembly. Ann N Y Acad Sci 466:745–756, 1986. 114. Pedersen-Bjergaard J: Insights into leukemogenesis from therapy-related leukemia. N
84. Dyke RW: Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med Engl J Med 352:1591–1594, 2005.
321:1270–1271, 1989. 115. Binaschi M, Zunino F, Capranico G: Mechanism of action of DNA topoisomerase
85. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 332:1004–1014, 1995. inhibitors. Stem Cells 13:369–379, 1995.
86. Lopes NM, Adams EG, Pitts TW, Bhuyan BK: Cell kill kinetics and cell cycle effects of taxol 116. Bugg BY, Danks MK, Beck WT, Suttle DP: Expression of a mutant topoisomerase II in
on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235–242, 1993. CCRF-CEM human leukemia cells selected for resistance to teniposide. Proc Natl Acad
87. Zaffaroni N, Pennati M, Colella G, et al: Expression of the anti-apoptotic gene sur- Sci U S A 88:7654–7658, 1991.
vivin correlates with Taxol resistance in human ovarian cancer. Cell Mol Life Sci 59: 117. Zwelling LA, Hinds M, Chan D, et al: Characterization of an amsacrine-resistant line
1406–1412, 2002. of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol
88. Anand S, Penrhyn-Lowe S, Venkitaraman AR: AURORA-A amplification overrides the Chem 264:16411–16420, 1989.
mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51–62, 118. Stewart CF, Arbuck SG, Fleming RA, Evans WE: Changes in the clearance of total and
2003. unbound etoposide in patients with liver dysfunction. J Clin Oncol 8:1874–1879, 1990.
89. Gianni L, Viganò L, Locatelli A, et al: Human pharmacokinetic characterization and in 119. Winick NJ, McKenna RW, Shuster JJ, et al: Secondary acute myeloid leukemia in
vitro study of the interaction between doxorubicin and paclitaxel in patients with breast children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:
cancer. J Clin Oncol 15:1906–1915, 1997. 209–217, 1993.
90. Semb KA, Aamdal S, Oian P: Capillary protein leak syndrome appears to explain 120. Ratain MJ, Kaminer LS, Bitran JD, et al: Acute nonlymphocytic leukemia following
fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16: etoposide and cisplatin combination chemotherapy for advanced non-small-cell carci-
3426–3432, 1998. noma of the lung. Blood 70:1412–1417, 1987.
91. Rivera E, Lee J, Davies A: Clinical development of ixabepilone and other epothilones in 121. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with
patients with advanced solid tumors. Oncologist 13:1207–1223, 2008. bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol
92. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new deriv- 6:1368–1376, 1988.
ative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 122. Yeager AM, Kaizer H, Santos GW, et al: Autologous bone marrow transplantation in
8:1907–1912, 1990. patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with
93. Beran M, Kantarjian H, O’Brien S, et al: Topotecan, a topoisomerase I inhibitor, is 4-hydroperoxycyclophosphamide. N Engl J Med 315:141–147, 1986.
active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leu- 123. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-
kemia. Blood 88:2473–2479, 1996. cancer chemotherapy. Cancer Treat Rev 24:331–344, 1998.
94. Beran M, Estey E, O’Brien S, et al: Topotecan and cytarabine is an active combination 124. Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are
regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin prognostic factors in advanced non-small-cell lung cancer patients treated with plati-
Oncol 17:2819–2830, 1999. num chemotherapy. J Clin Oncol 22:2594–2601, 2004.
95. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of Topotecan, a new topoisomerase I 125. Tew K, Colvin M, Jones R, et al: Alkylating agents, in Cancer Chemotherapy and Bio-
inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146–1151, 1993. therapy: Principles and Practice, 4th ed, edited by p 297. 2006.
96. Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of 126. Hilton J: Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leuke-
irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 mia. Cancer Res 44:5156–5160, 1984.
in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J 127. Erickson LC: The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug
Clin Invest 101:847–854, 1998. resistance and strategies for its inhibition. Semin Cancer Biol 2:257–265, 1991.
97. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynam- 128. Hunter C, Smith R, Cahill DP, et al: A hypermutation phenotype and somatic MSH6
ics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706–713, 1992. mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer
98. Rowinsky EK, Kaufmann SH, Baker SD, et al: A phase I and pharmacological study of Res 66:3987–3991, 2006.
topotecan infused over 30 minutes for five days in patients with refractory acute leuke- 129. Droller MJ, Saral R, Santos G: Prevention of cyclophosphamide-induced hemorrhagic
mia. Clin Cancer Res 2:1921–1930, 1996. cystitis. Urology 20:256–258, 1982.
99. Creutzig U, Zimmermann M, Bourquin JP, et al: Randomized trial comparing liposo- 130. Leoni LM, Bailey B, Reifert J, et al: Bendamustine (Treanda) displays a distinct pattern
mal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: of cytotoxicity and unique mechanistic features compared with other alkylating agents.
Results from Study AML-BFM 2004. Blood 122:37–43, 2013. Clin Cancer Res 14:309–317, 2008.
100. Péan E, Flores B, Hudson I, et al: The European Medicines Agency review of pixantrone 131. Elias AD, Eder JP, Shea T, et al: High-dose ifosfamide with mesna uroprotection: A
for the treatment of adult patients with multiply relapsed or refractory aggressive non phase I study. J Clin Oncol 8:170–178, 1990.
-Hodgkin’s B-cell lymphomas: Summary of the scientific assessment of the committee 132. Gianni AM, Bregni M, Siena S, et al: Recombinant human granulocyte-macrophage
for medicinal products for human use. Oncologist 18:625–633, 2013. colony-stimulating factor reduces hematologic toxicity and widens clinical applicability
101. O’Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha and responsiveness of breast of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin’s lym-
cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644–650, 2009. phoma. J Clin Oncol 8:768–778, 1990.
102. Press MF, Sauter G, Buyse M, et al: Alteration of topoisomerase II-alpha gene in human 133. Lazarus HM, Reed MD, Spitzer TR, et al: High-dose i.v. thiotepa and cryopreserved
breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat
Clin Oncol 29:859–867, 2011. Rep 71:689–695, 1987.

Kaushansky_chapter 22_p0313-0352.indd 348 9/18/15 10:26 PM